demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
adjuvant therapies
anticoagulant
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... COVID-PACT REMAP-CAP, ACTIV-4a, ATTACC ...
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ...

4 studies excluded by filtering options 0

5355 Paranjpe, 2020 1134not a RCThigh risk of bias
5895 X-COVID-19, 2021 010selection pending
5967 Gorenstein, 2020 000selection pending
6283 Lynn, 2020 0130selection pending